Description
Fingolimod (fingolimod) is a neurology medications agent listed in our Neurology medications directory and prescribed for multiple sclerosis (2.1). Administered via the oral route, Fingolimod is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Fingolimod is a medication containing the active pharmaceutical ingredient fingolimod, classified pharmacologically as a neurology medications agent (2.1). It is clinically indicated for the management of multiple sclerosis as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the Neurology medications section of our catalogue, patients and prescribers frequently review Fingolimod alongside related therapies such as Gilenya (Fingolimod), Almotriptan, Amantadine Hydrochloride, and Aricept (Donepezil Hydrochloride).
Official Indications and Usage
Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. (2.1)
Mechanism of Action and Pharmacology
Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. (2.1)
What is Multiple sclerosis?
Multiple sclerosis affects the central nervous system. Treatments may address disease activity, relapses, or particular symptoms. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Multiple sclerosis condition guide for appointment questions and related therapies (2.1).
Ordering Fingolimod from Canada for U.S. Delivery
U.S. patients can order Fingolimod (Fingolimod) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax 1-888-804-1287.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$14.99 USD Tracked Parcel
- Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Fingolimod |
| Chemical / Generic Name | Fingolimod |
| Pharmacological Class | Neurology medications agent |
| Therapeutic Category | Neurology medications |
| Same-Ingredient Catalogue Entries | Gilenya (Fingolimod) |
| Molecular Weight | 343.93 g/mol (2.1) |
| Bioavailability | ~93% (2.1) |
| Elimination Half-Life | ~6 to 9 days (2.1) |
| Legal Status | Rx-Only (Prescription Required) |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus |
| Routes of Administration | Oral |
| Dosage Forms & Strengths | Fingolimod Capsules are available as: 0.5 mg capsules are size “3” hard gelatin capsules having white opaque cap imprinted “0.5 mg" and white opaque body |
| Primary Indications | Multiple Sclerosis |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| FDA UNII Identifier | G926EC510T |
| NLM RxNorm Concept ID (RxCUI) | 1012895 |
| FDA Application License | ANDA207993 |
| Official DailyMed SetID | bd981e18-1766-4a2d-9a9b-965ec960aa06 |
| Catalogue Index Links | Letter F Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
Assessments are required prior to initiating Fingolimod Capsules Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): oObserve all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. OMonitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. OMonitor symptomatic bradycardia with ECG until resolved. (2.1)
Presentations and Strengths
Fingolimod Capsules are available as: 0.5 mg capsules are size “3” hard gelatin capsules having white opaque cap imprinted “0.5 mg" and white opaque body imprinted "MF" with black ink, filledwith white to off white colored fine powder. 0.5 mg hard capsules. (2.1)
Administration Guidance
Take Fingolimod orally at the same time(s) each day as directed on your prescription label (2.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.
Missed Dose Guidance
If you miss a scheduled dose of Fingolimod, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Fingolimod is fingolimod (2.1). Other catalogue entries containing fingolimod include Gilenya (Fingolimod).
Inactive Ingredients (Excipients)
According to the U.S. FDA product labeling, formulation excipients include fumaric acid, stearic acid, pregelatinized starch and empty hard gelatin capsules (2.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.
Cautions and important safety information
Contraindications
Fingolimod Capsules are contraindicated in patients who have: in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (tia), decompensated heart failure requiring hospitalization or Class III/IV heart failure a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker a baseline QTc interval ≥ 500 msec cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in Fingolimod Capsules. (2.1)
Key Clinical Precautions
Before starting or continuing Fingolimod, discuss your complete medical history with your healthcare provider. Key clinical cautions include (2.1):
- Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
- Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
- Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
- Increased susceptibility to infection: Therapies that modulate immune or metabolic pathways can increase the risk of bacterial, mycotic (fungal), viral, or opportunistic infections. Report fever, persistent cough, painful urination, or localized infection promptly.
- Malignancy monitoring: Follow age-appropriate and treatment-specific screening recommendations discussed with your prescribing specialist.
- Hepatic (liver) effects: Elevations in liver enzymes or rare cases of severe hepatic injury have been reported. Baseline and periodic liver function tests may be recommended; seek medical evaluation for jaundice, dark urine, or persistent right-upper-abdominal pain.
Pregnancy, Lactation, and Special Populations
Available observational pregnancy registry data suggest that use of Fingolimod Capsules are associated with an increased prevalenceof major birth defects in comparison to the general population. However, limitations in the number of exposed pregnant women and inthe study design preclude definitive conclusions. Data from prospective reports to the pregnancy registry are currently notsufficient to allow for an adequate assessment of the drug-associated risk for miscarriage. Based on findings from animal studies, Fingolimod Capsules may cause fetal harm when administered to a pregnant woman. (2.1)
Interactions
Official Drug Interaction Overview
Systemic Ketoconazole: Monitor during concomitant use. Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping fingolimod treatment. (2.1)
Important Interaction Categories
Concomitant use of Fingolimod with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):
- Digoxin (such as Lanoxin (Digoxin) or Digoxin Generic): Co-administration can affect P-glycoprotein transport or renal clearance of digoxin, altering serum digoxin concentrations. Appropriate clinical and laboratory monitoring of digoxin levels is advised.
Side effects
Like all medications, Fingolimod can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (2.1):
- Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
- Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
- Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
- Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
- Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.
- Pruritus (mild itching): Report any spreading rash, hives, or mucosal irritation to your healthcare provider.
Clinical Trial and Postmarketing Adverse Reactions
The following serious adverse reactions are described elsewhere in labeling: Bradyarrhythmia and Atrioventricular Blocks Infections Progressive Multifocal Leukoencephalopathy Macular Edema Liver Injury Posterior Reversible Encephalopathy Syndrome Respiratory Effects Fetal Risk Severe Increase in Disability After Stopping Fingolimod Capsules Tumefactive Multiple Sclerosis Increased Blood Pressure Malignancies Immune System Effects Following Fingolimod Capsules Discontinuation Hypersensitivity Reactions Most common adverse reactions (incidence ≥ 10% and greater than placebo): Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity. (2.1)
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Handling Fingolimod Capsules should be stored at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). Protect from moisture. (2.1)
Store Fingolimod in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (2.1).
What is a generic drug?
A generic medication contains the exact same active pharmaceutical ingredient (fingolimod) as its brand-name counterpart and is formulated to deliver the same dosage strength, route of administration, safety profile, quality, and therapeutic performance (2.1). Regulatory authorities require generic manufacturers to demonstrate bioequivalence, meaning the generic medication releases its active ingredient into the bloodstream at virtually the same rate and to the same extent as the innovator brand.
While a generic tablet, capsule, or inhaler may differ in color, shape, scoring, or packaging due to trademark laws that govern brand appearance, its clinical mechanism and active ingredient match the reference medicine. Because generic manufacturers do not repeat the initial discovery and multi-phase clinical trial investments of the original brand, generic equivalents offer substantial cost savings for patients paying out of pocket.
Canadian Pharmacy Store delivers prescription and over-the-counter medications to U.S. residents. Browse our Neurology medications directory, explore all medications A-Z, review how ordering works and prescription requirements, or call 1-888-868-1920 for personal assistance matching your prescription.
Related Medications in Our Catalogue
- Gilenya (Fingolimod), listed in Neurology medications
- Almotriptan, listed in Neurology medications
- Amantadine Hydrochloride, listed in Neurology medications
- Aricept (Donepezil Hydrochloride), listed in Neurology medications
- Ajovy (Fremanezumab), listed in Neurology medications
- Axert (Almotriptan), listed in Neurology medications
Related Categories, Directories, and Ordering Guides
- Neurology medications Category Directory
- Medications Starting with F
- Active Ingredient Directory
- What to prepare before a prescription order
- How to compare prescription prices without mixing up the product
- How to Order Prescription Medication
- Prescription Requirements
- Ordering Medication from Canada Guide
- Caregiver Ordering Guide
- Explore Medications
- Explore Categories
- Explore Lanoxin Digoxin
- Explore Digoxin Generic
Frequently Asked Questions About Fingolimod
What is Fingolimod and what active ingredient does it contain?
Fingolimod is a neurology medications agent containing the active pharmaceutical ingredient fingolimod. It is supplied for oral administration and requires a valid prescription where applicable.
How does Fingolimod work in the body?
Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.
What conditions is Fingolimod prescribed to treat?
Fingolimod is primarily indicated for multiple sclerosis. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Fingolimod?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Fingolimod is administered via the oral route. Take or apply it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Fingolimod?
Commonly reported side effects of Fingolimod include feeling sick, loose stools, headache, dizziness, abdominal pain, and itching. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.
What medications or substances can interact with Fingolimod?
Important interaction categories for Fingolimod include digoxin. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.
Can Fingolimod be used during pregnancy or breastfeeding?
Official prescribing information highlights pregnancy-related precautions for Fingolimod. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.
Do I need a prescription to buy Fingolimod online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Fingolimod (Fingolimod) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
What is the brand-name version of Fingolimod (Fingolimod) at a Canada pharmacy?
Yes. Fingolimod is the bioequivalent generic formulation of brand-name Gilenya, containing the same active ingredient (Fingolimod) and strength options.
Brand: Gilenya
How is Fingolimod shipped to U.S. residents, and how much does shipping cost?
Fingolimod ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.
How can I send or transfer my Fingolimod prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Fingolimod prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to 1-888-804-1287. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Fingolimod are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Fingolimod. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) MedlinePlus Medical Encyclopedia: Multiple Sclerosis. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (3.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).
